<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02119039</url>
  </required_header>
  <id_info>
    <org_study_id>OPHT-070214</org_study_id>
    <nct_id>NCT02119039</nct_id>
  </id_info>
  <brief_title>Effect of CACICOL20 on Corneal Epithelial Healing After Cross-linking in Patients With Keratoconus</brief_title>
  <official_title>Effect of CACICOL20 on Corneal Epithelial Healing After Cross-linking in Patients With Keratoconus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <brief_summary>
    <textblock>
      CACICOL20 is an ophthalmic solution based on the technology of RGTAs (ReGeneraTingAgents). It&#xD;
      consists of large biopolymers, imitating the structure of heparansulphate. The protecting&#xD;
      effect on different biological tissues and enhancement of wound healing has been described in&#xD;
      several studies.&#xD;
&#xD;
      Keratoconus is a relatively common disease, with incidences ranging from 1.3 to 25 per&#xD;
      100,000 per year across different populations. Corneal collagen cross-linking represents a&#xD;
      treatment option for these patients, aiming to prevent progression of the disease via&#xD;
      stabilization of corneal microstructure. Corneal epithelial removal prior to the ultraviolet&#xD;
      A/riboflavin cross-linking procedure significantly improves the outcome of the intervention,&#xD;
      due to ameliorated distribution of riboflavin.&#xD;
&#xD;
      The aim of the present study is to investigate the effect of CACICOL20 on corneal epithelial&#xD;
      wound closure after collagen cross-linking in patients with keratoconus. Results may lead to&#xD;
      an improved management and pain reduction of patients with corneal epithelial defects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to closure of the epithelial wound</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Keratoconus</condition>
  <arm_group>
    <arm_group_label>RGTA OTR 4120 (CACICOL20)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Genteal HA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RGTA OTR 4120 (CACICOL20)</intervention_name>
    <arm_group_label>RGTA OTR 4120 (CACICOL20)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Genteal HA eye drops</intervention_name>
    <arm_group_label>Genteal HA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged over 18 years&#xD;
&#xD;
          -  Presence of keratoconus&#xD;
&#xD;
          -  Scheduled for corneal cross linking&#xD;
&#xD;
          -  No ophthalmic surgery in the 3 months preceding the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in a clinical trial in the previous 3 weeks&#xD;
&#xD;
          -  Topical use of aminoglycosid antibiotics&#xD;
&#xD;
          -  Use of therapeutic or refractive contact lenses after surgery&#xD;
&#xD;
          -  Known hypersensitivity to any component of the study medication or heparinoids or&#xD;
             heparin&#xD;
&#xD;
          -  Active ocular infection&#xD;
&#xD;
          -  Presence of any abnormalities preventing reliable measurements as judged by the&#xD;
             investigator&#xD;
&#xD;
          -  Pregnancy, planned pregnancy or lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>March 21, 2014</study_first_submitted>
  <study_first_submitted_qc>April 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2014</study_first_posted>
  <last_update_submitted>December 21, 2015</last_update_submitted>
  <last_update_submitted_qc>December 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Katarzyna J. Witkowska</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Cross-linking</keyword>
  <keyword>RGTA OTR4120 (CACICOL20)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

